glutathione redox system synthesis and its role in signaling Free Acid The glutathione system maintains the

Pulmonary fibrosis studies using bleomycin-induced injury show reduced inflammatory cell infiltration and interstitial thickness at doses of 2.6-260 g/mL/day

Synergistic Tissue Remodeling The GLOW protocol targets tissue remodeling from multiple angles simultaneously

Activation of SSAT1/ALOX15 axis aggravates cerebral ischemia/reperfusion injury via triggering neuronal ferroptosis

Phase 2 cagrilintide alone ~10.8% body weight reduction at 26 weeks (4.5mg) Phase 2 CagriSema combo ~15.6% body weight reduction at 32 weeks Phase 3 REDEFINE 1 ~22.7% body weight reduction at 68 weeks Phase 2 CagriSema combination trial The Phase 2 trial of CagriSema was published in The Lancet in 2023, and its results attracted immediate attention